Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

•CF is the best palliative regimen in adv. ESCC.•Panitumumab added to CF failed to improve survival.•Low sEGFR linked to better PFS. BackgroundPalliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor recep...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Markus Moehler, Annett Maderer, Peter Thuss‐Patience, Baruch Brenner, Jens Meiler, Thomas Jens Ettrich, Ralf‐Dieter Hofheinz, S. Al-Batran, Arndt Vogel, Lothar Mueller, Manfred P. Lutz, Florian Lordick, María Alsina, K Borchert, Richard Greil, Wolfgang Eisterer, Arno Schad, Julia Slotta‐Huspenina, Eric Van Cutsem, Sylvie Lorenzen
Format: Artigo
Jezik:engleski
Izdano: 2020
Online pristup:https://doi.org/10.1016/j.annonc.2019.10.018
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Internet

https://doi.org/10.1016/j.annonc.2019.10.018

Slični predmeti